ClinicalTrials.gg
Not yet recruitingNCT07949864Updated Nov 19, 2026

Right Ventricular Function After Successful Reopening of Right Coronary Versus Left Circumflex Chronic Total Occlusions

An observational study in Coronary Chronic Total Occlusion and Coronary Artery Disease, sponsored by Assiut University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Assiut University · Observational

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
160
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 27 studies in Coronary Artery Disease by Assiut University — 12 open to participants now, 12 under way, none of them phase 3. Coronary Artery Disease · Assiut University.

Planned enrollment
4th of 19
160 · median 112
Started
2027
with 1 other
Observational
19 of 27
10 open now
Primary completion
2029-01
later than 11 of 11 live
Registered
27th of 27
by date

Among the 27 studies in Coronary Artery Disease by Assiut University, this one is the 4th largest by planned enrollment of the 19 observational ones that give a count, is one of 2 that started in 2027, is one of 19 observational ones, reaches primary completion later than 11 of the 11 other live ones, and was the 27th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

12 of the 27 studies in Coronary Artery Disease by Assiut University are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Coronary Artery Disease by Assiut University, or all of them as a file.
02

Study summary

This study will compare changes in the function of the right side of the heart after successful treatment of a long-standing complete blockage in either the right coronary artery or the left circumflex coronary artery. Patients will receive catheter-based treatment because their clinical team has independently decided that it is appropriate; the study will not assign their artery or treatment technique.

The planned comparison includes 160 patients with successful treatment, with 80 in each artery group. Heart ultrasound will be performed within 14 days before the procedure and again six months afterward. A telephone follow-up will take place at three months. Conventional ultrasound measurements and speckle tracking, which measures deformation of the heart muscle, will be used to assess right ventricular function. The main comparison is the change in right ventricular free-wall longitudinal strain between the two groups.

Read the detailed description

Design and setting:

Prospective, single-centre observational cohort at Assiut University Heart Hospital, with consecutive recruitment within two prespecified vessel strata. Elective percutaneous coronary intervention (PCI) is selected independently of research participation. The operator determines the clinical PCI technique. No research treatment assignment, stress test, additional catheterization, experimental drug, biomarker assay or SAQ-7 questionnaire is required.

Cohort formation:

Baseline written consent and research echocardiography precede PCI. The main comparison comprises technically successful index procedures: residual stenosis less than 30% with final TIMI 3 flow. One index attempt per patient defines cohort entry. Unsuccessful procedures are recorded descriptively in the screening log and do not contribute to the primary successful-procedure comparison. Procedural complications do not retrospectively redefine technical success. The planned main cohort is 80 RCA and 80 LCX patients; this is distinct from the number of patients screened or consented before PCI.

Recruitment schedule:

Anticipated recruitment is from 1 January 2027 through 30 June 2028. Each participant is followed for six months after index PCI, with the specified visit window. Recruitment end is distinct from final outcome collection.

Assessments:

Baseline clinical and resting echo assessment occurs within 14 days before PCI; repeat baseline if an intervening acute event occurs. Angiographic anatomy, procedure strategy, result, complications and discharge treatment are recorded at the index admission. Three-month telephone contact, with a 14-day window, records vital status, symptoms, admissions and medication changes and reminds participants of the six-month visit. Six-month resting echo and clinical reassessment allow a 30-day window. Late assessments are retained for sensitivity analysis.

Imaging:

Conventional two-dimensional echocardiography and RV speckle tracking are performed using a Philips system with AutoStrain RV, after verification of installed software, native RVFWSL/RV4CSL outputs and image export. Manufacturer, model and software version are documented. An RV-focused apical four-chamber view is acquired, with at least three stable ECG-linked cycles. Patient-level outputs are averaged across three acceptable cycles. Native global free-wall strain is the primary measure; four-chamber strain includes the septum. Signed source values are preserved. Images with persistent tracking failure are not replaced by another endpoint. Conventional measurements include FAC, TAPSE, tissue-Doppler S-prime and RV basal diameter. LVEF, LV volumes, valve regurgitation, E/e-prime and estimated pulmonary artery systolic pressure provide clinical context. PASP is recorded only when technically measurable.

Anatomical characterization:

Coronary dominance, CTO location relative to major branches, previous target-territory infarction, collateral supply, residual coronary disease and J-CTO score are recorded. All dominance patterns are eligible. The LCX cohort is a disease comparator, not a healthy control.

Sample-size rationale:

The target of 160 successful cases uses assumed planning inputs: a 2-percentage-point between-group difference in individual strain magnitude change, a common change SD of 4 points, two-sided alpha 0.05 and 80% power. A noncentral-t calculation requires 64 complete patients per group, increased to 80 per group for 20% incomplete paired assessment. These assumptions are not direct RCA-versus-LCX effect estimates or established minimal clinically important differences. At an assumed 85% success rate, approximately 95 eligible attempts per vessel stratum may be needed; this is a planning estimate rather than observed local recruitment data.

Analysis:

The primary endpoint is compared using a two-sided Welch t test with a 95% confidence interval. Supportive ANCOVA models six-month strain magnitude with vessel group, baseline strain magnitude, baseline LVEF, age, prior myocardial infarction and coronary dominance. The primary complete-pair estimand concerns survivors with successful index PCI and interpretable baseline and follow-up imaging. Deaths, failed procedures, withdrawals and tracking failures are reported separately; post-death strain is not imputed. Missing survivor outcomes are addressed by multiple imputation when feasible and sensitivity analyses. Signed-strain analysis, patient-level bootstrap intervals and analysis excluding major interval events are prespecified sensitivity checks. Formal secondary testing of RV4CSL, FAC, TAPSE and S-prime uses Holm correction. Segmental strain and symptom analyses are exploratory. Clinical events are descriptive; the study is not powered for mortality or major cardiovascular events and does not establish a causal effect of PCI.

Quality and ethics:

A separate technical run-in of 10-15 cases checks acquisition and analysis feasibility. Twenty-five paired examinations are randomly selected for interobserver and intraobserver repeat analysis; readers are blinded to group and visit order where feasible. Written consent and required institutional and ethics approvals precede research procedures. Coded records and image files are stored securely with the identity key separately. Clinical care remains independent of participation.

03

Conditions studied

  • Coronary Chronic Total Occlusion
  • Coronary Artery Disease

Keywords

  • Right ventricular function
  • Right coronary artery
  • Left circumflex artery
  • Percutaneous coronary intervention
  • Speckle tracking echocardiography
  • Right ventricular free-wall longitudinal strain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Clinically stable adults attending Assiut University Heart Hospital with one native RCA or LCX chronic total occlusion and an independently established clinical indication for elective PCI. Consecutive eligible patients are assessed within each vessel stratum. The main comparison targets 80 technically successful index procedures in each group. Consent and baseline research imaging precede PCI; unsuccessful index procedures are recorded descriptively outside the main comparative cohort.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • Clinically stable, with one native right coronary or left circumflex coronary artery chronic total occlusion, defined by TIMI 0 flow and documented or estimated duration of at least three months.
  • Independently selected for clinically indicated elective PCI.
  • Sinus rhythm and interpretable baseline RV-focused echocardiographic images.
  • Written before research procedures.
  • For inclusion in the main comparison: technically successful index CTO PCI, defined as residual stenosis less than 30% with final TIMI 3 flow.

Exclusion criteria

Exclusion Criteria:

  • Acute coronary syndrome or myocardial infarction within 30 days.
  • Decompensated heart failure.
  • A second untreated chronic total occlusion.
  • Previous coronary artery bypass graft surgery.
  • Significant congenital heart disease.
  • Moderate or severe valvular heart disease.
  • Severe nonischemic pulmonary disease or pulmonary hypertension dominating RV dysfunction.
  • Persistent atrial fibrillation or paced rhythm preventing comparable analysis.
  • Inadequate baseline RV tracking.
  • Planned non-target revascularization during follow-up; clinically required other-vessel treatment should be completed before baseline when stable.

No arbitrary threshold is imposed. All coronary dominance patterns are eligible. Interval clinical deterioration, target-vessel failure, medication changes or clinically required subsequent revascularization do not retrospectively exclude an enrolled patient; they are recorded and follow-up is retained whenever possible.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
160 participants (estimated)
Patient registry
No

Groups and cohorts

  • Successful RCA CTO PCI

    Adults with one native right coronary artery chronic total occlusion undergoing clinically indicated elective PCI with residual stenosis less than 30% and final TIMI 3 flow. Target: 80 technically successful patients. Baseline and six-month conventional and speckle tracking echocardiography are compared. Clinical treatment is not assigned by the research protocol.

    Procedure: Clinically indicated RCA CTO PCI · Procedure: Resting conventional and RV speckle tracking echocardiography

  • Successful LCX CTO PCI

    Adults with one native left circumflex coronary artery chronic total occlusion undergoing clinically indicated elective PCI with residual stenosis less than 30% and final TIMI 3 flow. Target: 80 technically successful patients. Baseline and six-month conventional and speckle tracking echocardiography are compared. Clinical treatment is not assigned by the research protocol.

    Procedure: Clinically indicated LCX CTO PCI · Procedure: Resting conventional and RV speckle tracking echocardiography

Interventions

  • ProcedureClinically indicated RCA CTO PCI

    Elective PCI of a right coronary artery chronic total occlusion. The treating team selects the indication and technique independently of the research protocol; this is the observed clinical exposure.

  • ProcedureClinically indicated LCX CTO PCI

    Elective PCI of a left circumflex coronary artery chronic total occlusion. The treating team selects the indication and technique independently of the research protocol; this is the observed clinical exposure.

  • ProcedureResting conventional and RV speckle tracking echocardiography

    Resting ultrasound assessment within 14 days before index PCI and at six months, with a 30-day follow-up window. Includes RV free-wall and four-chamber strain and conventional RV measures. No stress test is required.

06

What researchers measure

Primary outcomes

  1. Change in right ventricular free-wall longitudinal strain magnitude

    Individual change is the absolute magnitude of six-month RV free-wall longitudinal strain minus its baseline absolute magnitude, measured in percentage points. Native Philips RVFWSL output is used and signed source values are retained. A positive magnitude change denotes greater systolic shortening. The primary comparison is the difference in mean individual change between the RCA and LCX cohorts. For illustration only, a change from -20% to -23% equals +3 percentage points in magnitude; this is not an observed result or the assumed between-group effect.

    Time frame: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Secondary outcomes

  1. Change in right ventricular four-chamber longitudinal strain magnitude

    Change in native RV4CSL magnitude, including free wall and septum, from baseline to six months, in percentage points. Positive change denotes greater shortening magnitude; signed source values are preserved.

    Time frame: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

  2. Change in right ventricular fractional area change

    Six-month minus baseline RV fractional area change (FAC), in percentage points. FAC is 100 times (end-diastolic area minus end-systolic area) divided by end-diastolic area in an RV-focused view.

    Time frame: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

  3. Change in tricuspid annular plane systolic excursion

    Six-month minus baseline TAPSE, in millimetres, measured by aligned M-mode at the lateral tricuspid annulus.

    Time frame: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

  4. Change in tricuspid annular systolic tissue-Doppler velocity

    Six-month minus baseline systolic S-prime velocity, in centimetres per second, measured by pulsed tissue Doppler at the lateral tricuspid annulus.

    Time frame: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

  5. Change in right ventricular basal diameter

    Six-month minus baseline RV basal diameter, in millimetres, measured in the RV-focused apical four-chamber view.

    Time frame: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

  6. Change in Canadian Cardiovascular Society angina class

    Baseline and six-month CCS angina class and individual class transitions are recorded. Classes I through IV indicate progressively greater limitation by angina; a lower class denotes improvement. This is an exploratory clinical secondary outcome.

    Time frame: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

  7. Change in New York Heart Association functional class

    Baseline and six-month NYHA functional class and individual class transitions are recorded. Classes I through IV indicate progressively greater functional limitation; a lower class denotes improvement. This is an exploratory clinical secondary outcome.

    Time frame: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

Other outcomes

  1. Change in basal right ventricular free-wall segmental longitudinal strain magnitude

    Exploratory six-month minus baseline magnitude change in basal RV free-wall peak systolic longitudinal strain, in percentage points, when supported by the installed software and acceptable tracking. Settings remain consistent across visits. Signed values are retained. Segments are not treated as independent patients.

    Time frame: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

  2. Change in mid right ventricular free-wall segmental longitudinal strain magnitude

    Exploratory six-month minus baseline magnitude change in mid RV free-wall peak systolic longitudinal strain, in percentage points, when supported by the installed software and acceptable tracking. Settings remain consistent across visits. Signed values are retained. Segments are not treated as independent patients.

    Time frame: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

  3. Change in apical right ventricular free-wall segmental longitudinal strain magnitude

    Exploratory six-month minus baseline magnitude change in apical RV free-wall peak systolic longitudinal strain, in percentage points, when supported by the installed software and acceptable tracking. Settings remain consistent across visits. Signed values are retained. Segments are not treated as independent patients.

    Time frame: Baseline (within 14 days before PCI) and six months after PCI (plus or minus 30 days)

07

Study locations

1 site
08

References and documents

Publications

  • Blessing R, Drosos I, Molitor M, Munzel T, Wenzel P, Gori T, Dimitriadis Z. Evaluation of right-ventricular function by two-dimensional echocardiography and two-dimensional speckle-tracking echocardiography in patients with successful RCA CTO recanalization. Clin Res Cardiol. 2023 Oct;112(10):1454-1462. doi: 10.1007/s00392-023-02259-4. Epub 2023 Aug 1. PubMed 37526696 ↗
  • Galassi AR, Vadala G, Werner GS, Cosyns B, Sianos G, Hill J, Dudek D, Picano E, Novo G, Andreini D, Gerber BLM, Buechel R, Mashayekhi K, Thielmann M, McEntegart MB, Vaquerizo B, Di Mario C, Stojkovic S, Sandner S, Bonaros N, Luscher TF. Evaluation and management of patients with coronary chronic total occlusions considered for revascularisation. A clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC, the European Association of Cardiovascular Imaging (EACVI) of the ESC, and the ESC Working Group on Cardiovascular Surgery. EuroIntervention. 2024 Feb 5;20(3):e174-e184. doi: 10.4244/EIJ-D-23-00749. PubMed 38343372 ↗
  • Mukherjee M, Rudski LG, Addetia K, Afilalo J, D'Alto M, Freed BH, Friend LB, Gargani L, Grapsa J, Hassoun PM, Hua L, Kim J, Mercurio V, Saggar R, Vonk-Noordegraaf A. Guidelines for the Echocardiographic Assessment of the Right Heart in Adults and Special Considerations in Pulmonary Hypertension: Recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2025 Mar;38(3):141-186. doi: 10.1016/j.echo.2025.01.006. PubMed 40044341 ↗

Individual participant data

Plan to share: No — The IPD might not be shared according to the local institutional policy.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2029, 24 months later.

Of 636 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 24 months is below that.

Counting every sponsor, half of 761 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2026
First posted
Nov 19, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Jan 31, 2029
CompletionEst.
Jan 31, 2029
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949864
Lead sponsor
Assiut University
Responsible party
Amr Abdelbadee Abdelhameed Othman (Principal Investigator, Assiut University) — Principal investigator
First posted
Nov 19, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Jan 31, 2029 (estimated)
Completion
Jan 31, 2029 (estimated)
Last update
Nov 19, 2026

Study contacts

Amr A. A. Othman
Contact
amr.osman@med.aun.edu.eg
+201004674109
Hatem A. Helmy, MD
study chair · Department of Cardiovascular Medicine, Faculty of Medicine, Assiut University
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion